NRC FORM 374 U.S.	NUCLEAR REGULATORY COMMISSION	PAGE <u>1</u> OF <u>4</u> PAGES Amendment No. 48				
MATERIALS LICENSE						
Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable reles, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.						
Licensee	In accordance	with letter dated				
	August 21, 20					
1. Covenant Medical Center, Inc.		3. License number 21-01492-02 is amended				
	in its entirety t	o read as follows:				
2. 1447 N. Harrison	4. Expiration dat	e December 31, 2014				
Saginaw, MI 48602	5. Docket No. 0	30-02012				
	Reference No					
 Byproduct, source, and/or special nuclear material Chemical and/or Rhystcal form Maximum amount that licensee may possess at any one time under this license 						
A. Any byproduct material 5 permitted by 10 CFR 35.	A. Any	A. As needed				
B. Any byproduct material permitted by 10 CFR/35.200	Any	B. As needed				
C. Any byproduct material permitted by 10 CFR 35.300	I run	C. CAs needed				
D. lodine-125 permitted by 10 CFR 35.400	D. Standes Model No. 3500 Med Physics Altershap Mentor Med No. 4505 Mentor Med No. 4525SL or I-125 and IsoAld L.L.C., Model IAI-125A	D. 31.15 curies				
E. Any byproduct material permitted by 10 CFR 31.11	E. Propockated to s	E. As needed				
9. Authorized Use:						
A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.						
B. Any imaging and localization st	B. Any imaging and localization study permitted by 10 CFR 35.200.					
C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.						
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.						
E. <u>In vitro</u> studies.						

NRC FOR	M 374A U.S. NUCLEAR REGULATORY COMMIS	SION PAGE 2 of 4 PAGES			
		License Number 21-01492-02			
MATERIALS LICENSE SUPPLEMENTARY SHEET		Docket or Reference Number 030-02012			
		Amendment No. 48			
	CONDITI	ONS			
10. A.	 A. Licensed material, excluding 6.D., may be used at the licensee's facilities located at 700 Cooper Avenue, Saginaw, Michigan. 				
В.	B. Licensed material, excluding iodine-131 for thyroid carcinoma therapies may be used at the licensee's facilities located at 5400 Mackinaw Road, Saginaw Michigan.				
11. The	11. The Radiation Safety Officer for this license is Biren Shah, M.D.				
12. Lice	12. Licensed material is only authorized for psetby, or under the supervision of:				
A.					
Β.	The following individuals are authorized users fo	r medical uses			
	Authorized User	ial ana tanàna amin'ny fisiana amin'ny fisiana amin'ny fisiana amin'ny fisiana amin'ny fisiana amin'ny fisiana			
	Joseph E. Talbot, M.D.	R 35(11, 35.200 and 35.300.			
	Scott E. Cheney, M.D.	and 35.200.			
	Sanjay J. Talati, M.D.	35.100 35.200.			
	Ram K. Gadam, M.D.	1.35. (2) , 35.200, 6 nd 35.300.			
	George F. Ascherl, M.D.	R 35.100, 35.200 and 35.300.			
	Harvey Yee, M.D.	F 35, 10, 35.200 and 35.300.			
	C.E. Mueller, M.D.	R 35.100, 35.200, 35.300 and 31.11.			
	Robert B. Saltzman, M.D. 10 CF	R 35.100, 35.200, 35.300 and 31.11.			
	Tyre K. Jones, M.D. 10 CF	R 35.100, 35.200 and 35.300.			
	Mark Robert Ludka, M.D. 10 CF	R 35.100, 35.200, 35.300 and 31.11.			
	Kristin M. Nelsen, M.D. 10 CF	R 35.100, 35.200, and 31.11.			

NR	C FORM 374A	U.S. NUCLEAR REGULATOR		PAGE 3 of 4 PAGES
				License Number 21-01492-02
MATERIALS LICENSE SUPPLEMENTARY SHEET		Docket or Reference Number 030-02012		
			Amendment No. 48	
			<u></u>	
	Rajnikan	t H. Mehta, M.D.	10 CFR 35	.400.
	Rajesh F	P. Kotecha, M.D.	10 CFR 35	.400.
	Paul G. I	Kocheril, M.D.	10 CFR 35	.400.
	James F	. Littles, M.D.	10 CFR 35	.400.
	Sigrid E.	Messana, D.O.	10 CFR 35	.100, 35.200, and 31.11.
	Chirdee	p Bhutani, M.D.	10 CFR 35	.100, 35.200 and 35.300.
	Curtis Br	asseur, D.O.	18 CER 35	.100, 35.200, and 31.11.
	Sambasi	va Kottamasu, M. Q .		.100, 35.200, 35.300 and 31.11
	Ramesh	Vedula, M.D.	10 CFR 35	0.400. P
	Gualbert	o Buzon, MD.	10 CFR 35	35.200
	Biren A.	Shah, M.D.	TO CFR 35	35.200 and 35.300
	James F	. Finch, D . O.		CO apr 35.200
	Rita Rata	ani, M.D.		.100
	Rajinder	P. Singh, M.D.		35.200 and 35.300
13.	The licensee "Packaging a	may transport licensed material nd Transportation of Radioactive	intercordance Materials."	ce with the povisions of 10 CFR Part 71,
14.	14. In addition to the possession limits in Item anthemenisse shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.			
15.	15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.			

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSIO	License Number			
	21-01492-02 Docket or Reference Number			
MATERIALS LICENSE SUPPLEMENTARY SHEET	030-02012			
	Amendment No. 48			
	· ·			
A. Application dated September 24, 2004.				
B. Letters dated August 21, 2006, and December 4	, 2006.			
R R F	Gu			
AUCLEAR RE.	GULA			
	P			
	O R			
- A Muun				
o Second				
	S S			
1, - 44, -				
*				
FOR TH	HE U.S. NUCLEAR REGULATORY COMMISSION			
	~			
DEC 2 2 2006	market Muller			
Jan	es R. Mullauer, M.H.S.			
	erials Licensing Branch ion III			